Compare FSP & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | FLNA |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 30.0M |
| IPO Year | 2001 | 2000 |
| Metric | FSP | FLNA |
|---|---|---|
| Price | $0.38 | $0.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | ★ 591.3K | 462.6K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | $41,119,000.00 |
| Revenue This Year | $16.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.39 |
| 52 Week High | $1.05 | $2.03 |
| Indicator | FSP | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 55.81 |
| Support Level | $0.31 | $0.43 |
| Resistance Level | $0.40 | $0.68 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 9.57 | 93.03 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.